Mogrify: Using Big Data To Transform Development Of Cell Therapies
Executive Summary
Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.
You may also be interested in...
Deals Shaping Medtech And Diagnostics, September 2021
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.
Deals Shaping The Medical Industry, September 2021
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.
Snapshot: September Highlights
A selection of articles you might have missed from September 2021, including exclusive interviews and a look at pharma marketing trends in 2021.